VIENNA, Va.–(BUSINESS WIRE)–
CEL-SCI Corporation (NYSE MKT: CVM) today announced that in March it has enrolled 29 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). March marks the third consecutive month of record enrollment for CEL-SCI this year following January and February 2015. 406 patients have been enrolled in the Phase III study as of March 31, 2015.
“The accelerating pace of enrollment in our trial is very good. We expect to see continued increases in monthly patient enrollment throughout the year as new clinical centers are added and as existing centers gain more experience with Multikine,” stated CEL-SCI Chief Executive Officer Geert Kersten.
About Multikine Phase III Study
The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.
